Clinical trials: Residual Disease
Speech Sound Disorder
Delineation of Sensorimotor Subtypes Underlying Residual Speech Errors
Children with speech sound disorder show diminished accuracy and intelligibility in spoken communication and may thus be perceived as less capable or intelligent than peers, with negative consequences for both socioemotional and…
- Trial name
- C-RESULTS (NCT03736213)
- Testing
- Visual-acoustic biofeedback, Ultrasound biofeedback
- Where
- 3 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- New York University
Hemophilia A
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity, during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270 on usage of exogenous FVIII replacement…
- Trial name
- GENEr8-2 (NCT03392974)
- Testing
- Valoctocogene Roxaparvovec
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- BioMarin Pharmaceutical
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH
Barrett's Esophagus
Cryo Balloon for Residual Barrett's Esophagus
This study is being done to see if treating residual Barrett's Esophagus after previously having undergone Radiofrequency ablation or Endoscopic Mucosal resection can be eliminated with focal cryotherapy.
- Trial name
- Cryoballoon (NCT02230410)
- Testing
- CryoBalloon Focal Ablation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Type 1 Diabetes
The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)
The primary aim of this pilot study is to test whether gluten-free diet (GFD) instituted in children shortly after onset of Type 1 Diabetes (T1D) can decelerate the decline in beta cell function as compared to age matched…
- Trial name
- NCT02867436
- Testing
- Gluten-free diet
- Where
- 2 sites in Czechia
- Volunteers
- 45 people
- Sponsor
- University Hospital, Motol
Morbid Obesity, Bariatric Surgery Candidate
EPO2-PV: Evaluation of Pre-Oxygenation Conditions in Morbidly Obese Volunteer: Effect of Position and Ventilation Mode
The risk of complications associated with airway management in obese patients is significant. The results of pre-oxygenation allow a prolonged non-hypoxic apnea time for the clinician.
- Trial name
- EPO2-PV (NCT02121808)
- Testing
- NIPPV, Tidal volume
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laval University
Lung Cancer
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
It is apparent that local control for Non-small Cell Lung Cancer (NSCLC) remains a significant problem. Conventional radiation therapy techniques have limitations for the dose that can be delivered to a chest tumor mass due to…
- Trial name
- NCT01657617
- Testing
- Boost Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ronald McGarry
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Dupuytren's Disease
Collagenase in the Treatment of Dupuytrens Disease
The purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with Dupuytren's disease.
- Trial name
- NCT00260429
- Testing
- collagenase clostridium histolyticum
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stony Brook University
Carcinoma, Non- Small Cell Lung
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
- Trial name
- MERMAID-2 (NCT04642469)
- Testing
- Durvalumab
- Where
- 115 sites in United States, Argentina and 23 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT03537599
- Testing
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sumithira Vasu
Breast Cancer
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the…
- Trial name
- NCT01772472
- Testing
- trastuzumab, trastuzumab emtansine
- Where
- 268 sites in United States, Argentina and 26 more
- Volunteers
- 1,486 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
This is a non-randomized, open-label, multicenter, dose escalation study designed to determine the maximum tolerated dose (MTD) of SL-401 in adult patients with acute myeloid leukemia, and to evaluate the safety profile of SL-401…
- Trial name
- NCT02270463
- Testing
- Tagraxofusp-erzs
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Major Depressive Disorder
A Study of Patients With Major Depressive Disorder and Residual Apathy
The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a…
- Trial name
- NCT00985504
- Testing
- Duloxetine, Escitalopram
- Where
- 15 sites in Australia, Canada and 3 more
- Volunteers
- 483 people
- Sponsor
- Eli Lilly and Company
Healthy Subjects, Sleep Initiation and Maintenance Disorders
An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.
- Trial name
- NCT00699608
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Phantom Limb Pain, Residual Limb Pain
Pulsed Electromagnetic Fields for Post-Amputation Pain
Pulsed electromagnetic field therapy is a possible method of pain control involving the application of electromagnetic energy (also termed nonthermal, pulsed, shortwave radiofrequency therapy).
- Trial name
- NCT05392803
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Diego
HIV Infection
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
This study is a prospective, open-label, randomized, three-arm, dose-escalation exploratory pilot clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy…
- Trial name
- ACTIVATE (NCT02471430)
- Testing
- Panobinostat, Pegylated Interferon-alpha2a
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital